Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial

Biosimilar vs Innovator Cetuximab in Indian Head & Neck Cancer Patients

Bibliographic Details

Published in:	JCO global oncology Vol. 10; no. 10; p. e2400059
Main Authors:	Prabhash, Kumar, Deshmukh, Chetan, Malhotra, Hemant, Sharma, Atul, Jain, Minish, Dhamne, Nilesh, Nagarakar, Rajnish, Ganesan, Prasantha, Mahobia, Vijay K., Das, Chandan K., Kumar, Rejnish, Shivanna, Prakash S., Avaronnan, Manu P., Chaithanya, Puligundla K., Chaudhary, Vaibhav, Singh, Kartar, Aagre, Suhas, Ravishankar, Bellala, Mehta, Dhruv, Shilpa, Kandipalli, Maniar, Vashishth, Chatterjee, Koushik, Majumdar, Saroj D., Dana, Rohitashwa, Noronha, Vanita, Menon, Nandini, Sharma, Akhilesh, Pawar, Roshan, Shahavi, Vinayaka, Yadav, Rajiv, Aiwale, Amol
Format:	Journal Article
Language:	English
Published:	American Society of Clinical Oncology 01-11-2024
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!